Scientific Advisory Board
Click on the name to see their biography.
Mr. Charles O. Hancock
Mr. Hancock is an American consultant recognized internationally as an expert in the field of sterilization methods. He counsels manufacturers of medical and surgical instruments, hospitals and governments. On the United Nations Environmental Program Working Group, which has the responsibility for applying the Montreal Protocol, he represents the United States as a scientific adviser on the replacement alternatives to ethylene oxide (ET0) in sterilization. Mr. Hancock is also Vice Chairman of the Canadian Standards Association Technical Committee for Sterilization. His consulting services to TSO3 include revision of the documentation intended for the FDA and inspections (« audits ») of procedural compliance with the GMP quality control system. He supervises the committee members and assures a good working relationship between the Company and the FDA.
Dr. James R. Husman
Dr. James R. Husman recently retired from 3M Company in St. Paul, Minnesota with over 30 years experience in Technical and Executive Director Positions. His experience at 3M ranged from managing basic research and product development in Chemicals, Adhesives, Optical Products, Nonwoven Materials, Biomaterials, Medical Products, and Government Research and Development Contracts.
Dr. Husman was the Manager of 3M’s European Specialty Materials Laboratory in Antwerp, Belgium, Technical Director of 3M’s Medical Division, and Executive Director of Technical Operations for Sumitomo 3M in Tokyo, Japan with responsibility for research and development in 3M Korea.
Dr. Husman holds a PhD in Organic Chemistry from the University of New Hampshire with Post Doctoral Research in Biochemistry at the University of Oregon.
Mr. Bernard Legube
Professor Legube obtained a Ph.D. in Science at University of Poitiers, France in 1983 (specializing in water chemistry) by the acceptance of his thesis entitled « Mechanisms of ozonization of aromatic compounds in aqueous solution». He completed his postgraduate studies in "Ozonization of phenol and aquatic fulvic acid" at the University of North Carolina in the United States. He has conducted many research programs on oxidants such as ozone, chlorine, ozone/hydrogen peroxide and ozone/catalyst. He is the author of several publications on the oxidative mechanisms of ozone. Professor Legube is Vice President of the IANESCO-CHIMIE Poitiers (Laboratory for Water Analysis and Engineering Consulting Agency). His consultation services for TSO3 focus on the oxidative mechanisms of ozone.
Dr. Paul S. Malchesky
Dr. Malchesky holds a B.S. degree in Chemistry/Math from St. Francis College (PA) and an M.S. degree in Chemistry from Case Western Reserve University in Cleveland. He holds also an M.S. degree in Chemical Engineering and a Doctorate in Engineering, Chemical Engineering, from Cleveland State University. He is President of the International Center for Artificial Organs and Transplantation (ICAOT) and President of Malchesky & Associates, LLC, a firm specializing in providing consulting services to the medical device and chemical industries. As former Vice President, Research and Development, Scientific Services, and Investigational Studies at STERIS Corporation for almost 10 years, he led research and development teams on sterilization methods supervising many scientists and engineers. Previously at the CLEVELAND CLINIC FOUNDATION from 1969 to 1992, Dr. Malchesky headed world recognized research and development efforts with a multidisciplinary team of professionals in the field of artificial organ technologies.
He is an Associate Professor of Surgery, Baylor College of Medicine, Houston, Texas, an Adjunct Staff in Biomedical Engineering, Cleveland Clinic Foundation, Cleveland, OH, and an Adjunct Professor in Chemical Engineering at Kansas State University. Dr. Paul S. Malchesky has carried out and directed research and development in a variety of medical device and chemical related areas including sterilization processes and sterilant formulation and separation processes for diagnostic and therapeutic applications. He has published extensively in many medical fields and holds thirty one patents. Dr. Malchesky is active in various professional societies and is Editor-in-Chief of Artificial Organs, and is the Managing Editor of Therapeutic Apheresis and Dialysis.
Dr. Richard Marchand
Dr. Marchand completed his Medical Studies at the Université de Montréal in 1980. From 1980 to 1986, he did his internship in internal medicine, medical microbiology and infectious diseases. He obtained a Fellowship in microbiology and immunology at the Centre for Pediatric Research at Saint-Justine Hospital in Montreal. He has been a microbiologist and immunologist at the Montreal Heart Institute. Dr. Marchand is also a clinical assistant-professor at the microbiology and immunology department of Université de Montréal. His services to TSO3 include consultation on clinical microbiology, sterility control methods and composing protocols for clinical tests. Dr. Marchand is also responsible for the testing of the 125L ozone sterilizer for prion inactivation.
Mr. Gregg A. Mosley
On January 28, 2006, Mr. Gregg A. Mosley joined the Advisory Board of the Company. He is an internationally recognized authority in GMP compliance, sterilization and manufacturing of sterile medical products, serves as an independent consultant to the pharmaceutical and medical device industry in the area of process validation and sterilization. He has authored papers and collaborated in presentations and courses for the Food and Drug Administration (FDA), the Parenteral Drug Association (PDA), Medical Device and Diagnostic Industries (MD & DI), American Society of Microbiology (ASM), and workshops for the International Society of Pharmaceutical Engineers (ISPE).